Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial
The Journal of Infectious Diseases · 23.09.2024 · 230 (3) · e668-e678
DOI: 10.1093/infdis/jiae114 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 13.03.2024. Verfasst von Carlos Fierro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Johnson County Clin-Trials, Department of Clinical Safety & Risk Management, Lenexa, Kansas. Hauptthemen laut MEDLINE: Antibodies, Viral, Cytomegalovirus, Cytomegalovirus Infections, Cytomegalovirus Vaccines. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.
Abstract (Originalsprache)
Background
This phase 1 trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1647, a messenger RNA (mRNA)–based cytomegalovirus (CMV) vaccine, in CMV-seronegative and -seropositive adults.
Methods
Participants were randomly assigned to receive 30, 90, 180, or 300 µg of mRNA-1647 or placebo on a 0-, 2-, and 6-month schedule and followed for 12 months after the last dose.
Results
A total of 154 (80 CMV-seronegative and 74 CMV-seropositive) participants were enrolled; 118 participants were randomized to mRNA-1647 and 36 to placebo. Mean (standard deviation) age was 32.5 (8.6) and 35.1 (8.9) years in the placebo and mRNA-1647 groups, respectively, in phase B (63% and 64% female) and 42.5 (6.2) and 33.3 (8.7) years, respectively, in phase C (2% and 16% female). No deaths, related serious adverse events, or adverse events of special interest were reported. Most adverse reactions were grade ≤2 severity. Increased neutralizing antibody, binding antibody, and antigen-specific cell-mediated responses were observed across mRNA-1647 treatment groups, regardless of CMV serostatus.
Conclusions
This phase 1, first-in-human trial demonstrated that mRNA-1647 has an acceptable safety profile in adults and elicits humoral and cellular immune responses. Clinical Trials Registration. NCT03382405.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johnson County Clin-Trials, Department of Clinical Safety & Risk Management, Lenexa, Kansas.
- Optimal Research, LLC, Peoria, Illinois.
- Advanced Clinical Research, Meridian, Idaho.
- Research Centers of America, LLC, Hollywood, Florida.
- Moderna, Inc, Department of Clinical Development Operations, Cambridge, Massachusetts.
- Moderna, Inc, Department of Biostatistics, Cambridge, Massachusetts.
Förderung
- Moderna, Inc
Zitieren
APA
Fierro, C., Brune, D., Shaw, M., Schwartz, H., Knightly, C., Lin, J., Carfi, A., Natenshon, A., Kalidindi, S., Reuter, C., Miller, J., & Panther, L. (2024). Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial. The Journal of Infectious Diseases, 230(3), e668-e678. https://doi.org/10.1093/infdis/jiae114
Vancouver
Fierro C, Brune D, Shaw M, Schwartz H, Knightly C, Lin J, et al. Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial. The Journal of Infectious Diseases. 2024;230(3):e668-e678. doi:10.1093/infdis/jiae114
BibTeX
@article{Fierro2024,
author = {Fierro, Carlos and Brune, Daniel and Shaw, Marian and Schwartz, Howard and Knightly, Conor and Lin, Jiang and Carfi, Andrea and Natenshon, Andrew and Kalidindi, Shiva and Reuter, Caroline and Miller, Jacqueline and Panther, Lori},
title = {Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {3},
pages = {e668--e678},
doi = {10.1093/infdis/jiae114}
}
EUVIMED